Fig. 3. Cell viability of (A) TF1 and HEL and (B) A549 and A431 cell lines treated with thiazole-based chalcones at 10 μM for 72 h. Data are represented as means ± SEM (n = 2). ** p ≤ 0.01, *** p ≤ 0.001 vs. ruxolitinib and ^##p ≤ 0.01, ^###p ≤ 0.001 vs. erlotinib.